We recognize that drugs for cardiovascular disorders currently available have the following two limitations.
1) Efficacy Limitations
The efficacy of these currently available medications is limited to symptomatic effects. Thus, an innovative drug providing a permanent therapeutic effect through the action of regenerating myocardial tissue is needed.
2) Limitations on Development
Drug discovery screening for drugs for cardiovascular disorders uses animal or cellular models (screening tools), which are genetically engineered to demonstrate a particular human disease.
To solve these problems, we have focused on the master gene inducing the differentiation of cardiomyocytes. The master gene for myocardium is a crucial gene that may be involved in myocardial generation, but has not been identified yet. We are eagerly and strategically striving to identify this gene.
1) Development of myocardial regenerative medicines
We are developing medicines that regenerate cardiac muscle by transferring the master gene or control its actions.
2) Development of research tools for drugs for cardiovascular disorders
We are developing cultured cells and experimental animals genetically engineered to demonstrate cardiovascular disorders using the master gene.Back to main contents